Lumykras 240mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Lumykras 240 mg tablets contain sotorasib, a targeted medicine that blocks the mutated KRAS G12C protein.
- Lumykras is the European brand name; the identical product is sold in the United States as Lumakras, so the two names refer to the same medicine and should not be counted as separate treatments.
- In the European Union, Lumykras is authorised as a single agent for adults with KRAS G12C-mutated advanced non-small cell lung cancer whose disease has progressed after at least one prior systemic therapy, under a conditional marketing authorisation granted on 6 January 2022 to Amgen Europe B.V. in the Netherlands.
- The United States label additionally covers KRAS G12C-mutated metastatic colorectal cancer in combination with panitumumab in previously treated adults.
- A validated test must confirm the KRAS G12C mutation before treatment starts, and treatment should be started by a doctor experienced in cancer medicines.
- It is taken at home by the patient.
Side Effects
- Sotorasib has no boxed warning on either the European or the United States label.
- In lung cancer trials of sotorasib alone, the most common side effects were diarrhoea in about 42 percent of patients, musculoskeletal pain in 35 percent, nausea in 26 percent, tiredness in 26 percent, abnormal liver blood tests or liver injury in 25 percent and cough in 20 percent.
- Vomiting, reduced appetite, headache and rash also occur.
- The two reactions that matter most are liver injury and inflammation of the lungs.
- Contact your care team promptly if you notice yellowing of the skin or eyes, dark urine, pale stools, pain under the right ribs or unusual tiredness, and seek urgent advice for new or worsening breathlessness, a dry cough or fever, which can indicate interstitial lung disease.
- Persistent or severe diarrhoea should also be reported so it can be treated early.
Precautions & Warnings
- The recommended dose is 960 mg once daily, taken as four 240 mg tablets swallowed whole at about the same time each day, with or without food; for side effects the dose may be reduced first to 480 mg and then to 240 mg daily rather than stopped.
- No regulator has changed the approved 960 mg starting dose.
- Liver function tests must be checked before starting, then every 3 weeks for the first 3 months and monthly thereafter, or more often if results are abnormal, and sotorasib is withheld or stopped for significant liver injury.
- Treatment is withheld immediately if interstitial lung disease or pneumonitis is suspected and stopped permanently if it is confirmed.
- Tablets should not be crushed or chewed; if swallowing is difficult, disperse as directed rather than improvising.
- Store at 20°C to 25°C.
- Discuss pregnancy, contraception and breastfeeding with your provider before starting, and report any new medicine you are prescribed.
Avoid Interactions
- Medicines that REDUCE the effect of Lumykras are the main concern.
- Sotorasib needs stomach acid to dissolve, so proton pump inhibitors such as omeprazole and H2 blockers such as famotidine should be avoided; if an antacid is needed, take Lumykras 4 hours before or 10 hours after a locally acting antacid.
- Strong CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin, phenobarbital and St John's wort also lower sotorasib levels and should be avoided.
- In the other direction, sotorasib can INCREASE blood levels of P-gp substrates such as digoxin, so these may need dose adjustment and monitoring, and it can alter the levels of some CYP3A4 substrates.
- Grapefruit juice affects CYP3A4 and is best avoided.
- Tell your prescriber and pharmacist about every prescription medicine, over-the-counter remedy, herbal product and supplement, especially indigestion remedies, before and during treatment.
References
Frequently Asked Questions
Lumykras (sotorasib) treats adults with advanced non-small cell lung cancer that carries the KRAS G12C mutation and has progressed after earlier systemic treatment. A test must confirm the mutation first. In the US, where it is sold as Lumakras, it is also approved with panitumumab for colorectal cancer.
The dose of Lumykras (sotorasib) is 960 mg once daily, taken as four 240 mg tablets swallowed whole at about the same time each day, with or without food. For side effects the dose may be lowered to 480 mg and then 240 mg daily.
Lumykras (sotorasib) commonly causes diarrhoea in about 42 percent of people, muscle and joint pain in 35 percent, nausea and tiredness in 26 percent each, and abnormal liver tests in 25 percent. Report yellow skin or eyes, dark urine, or new breathlessness and cough urgently.
Avoid proton pump inhibitors like omeprazole and H2 blockers like famotidine with Lumykras (sotorasib), as they cut absorption. If you need an antacid, take Lumykras 4 hours before or 10 hours after it. Avoid rifampicin, carbamazepine, phenytoin, St John's wort and grapefruit juice.
Liver function is checked before starting Lumykras (sotorasib), then every 3 weeks for the first 3 months and monthly after that, or more often if results are abnormal. About 25 percent of patients develop abnormal liver tests, and the dose may be withheld or stopped.
Yes. Lumykras is the European brand name for sotorasib and Lumakras is the United States brand name for the same medicine from Amgen. They are not two different treatments. The EU authorisation covers lung cancer only; the US label also covers colorectal cancer with panitumumab.

Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.